These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32774500)

  • 1. Somatic mutations in genes associated with mismatch repair predict survival in patients with metastatic cancer receiving immune checkpoint inhibitors.
    Liu Y; Chen L; Zhang S; Shu Y; Qi Q; Zhu M; Peng Y; Ling Y
    Oncol Lett; 2020 Oct; 20(4):27. PubMed ID: 32774500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
    Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
    Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinctive genomic characteristics in
    He J; Ouyang W; Zhao W; Shao L; Li B; Liu B; Wang D; Han-Zhang H; Zhang Z; Shao L; Li W
    Ann Transl Med; 2021 Jan; 9(2):129. PubMed ID: 33569431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types.
    Gong Z; Yang Y; Zhang J; Guo W
    Cancer Biol Med; 2021 May; 18(4):1080-91. PubMed ID: 33960179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs).
    Giustini N; Bazhenova L
    Lung Cancer (Auckl); 2021; 12():21-34. PubMed ID: 33790679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer.
    Sun L; Li M; Deng L; Niu Y; Tang Y; Wang Y; Guo L
    Front Pharmacol; 2021; 12():625593. PubMed ID: 33927616
    [No Abstract]   [Full Text] [Related]  

  • 7. Eight gene mutation-based polygenic hazard score as a potential predictor for immune checkpoint inhibitor therapy outcome in metastatic melanoma.
    Zhao L; Luo T; Jiang J; Wu J; Zhang X
    Front Mol Biosci; 2022; 9():1001792. PubMed ID: 36120536
    [No Abstract]   [Full Text] [Related]  

  • 8. Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort.
    Li Y; Chen Z; Wu L; Tao W
    Ann Transl Med; 2020 Apr; 8(7):446. PubMed ID: 32395490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.
    Antonarakis ES; Shaukat F; Isaacsson Velho P; Kaur H; Shenderov E; Pardoll DM; Lotan TL
    Eur Urol; 2019 Mar; 75(3):378-382. PubMed ID: 30337059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
    Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
    Front Oncol; 2019; 9():1161. PubMed ID: 31750249
    [No Abstract]   [Full Text] [Related]  

  • 12. Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.
    Geurts-Giele WR; Leenen CH; Dubbink HJ; Meijssen IC; Post E; Sleddens HF; Kuipers EJ; Goverde A; van den Ouweland AM; van Lier MG; Steyerberg EW; van Leerdam ME; Wagner A; Dinjens WN
    J Pathol; 2014 Dec; 234(4):548-59. PubMed ID: 25111426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
    Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M
    Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
    Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
    Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis.
    Olivares-Hernández A; Del Barco Morillo E; Parra Pérez C; Miramontes-González JP; Figuero-Pérez L; Martín-Gómez T; Escala-Cornejo R; Bellido Hernández L; González Sarmiento R; Cruz-Hernández JJ; Ludeña de la Cruz MD
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
    Samstein RM; Lee CH; Shoushtari AN; Hellmann MD; Shen R; Janjigian YY; Barron DA; Zehir A; Jordan EJ; Omuro A; Kaley TJ; Kendall SM; Motzer RJ; Hakimi AA; Voss MH; Russo P; Rosenberg J; Iyer G; Bochner BH; Bajorin DF; Al-Ahmadie HA; Chaft JE; Rudin CM; Riely GJ; Baxi S; Ho AL; Wong RJ; Pfister DG; Wolchok JD; Barker CA; Gutin PH; Brennan CW; Tabar V; Mellinghoff IK; DeAngelis LM; Ariyan CE; Lee N; Tap WD; Gounder MM; D'Angelo SP; Saltz L; Stadler ZK; Scher HI; Baselga J; Razavi P; Klebanoff CA; Yaeger R; Segal NH; Ku GY; DeMatteo RP; Ladanyi M; Rizvi NA; Berger MF; Riaz N; Solit DB; Chan TA; Morris LGT
    Nat Genet; 2019 Feb; 51(2):202-206. PubMed ID: 30643254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA mismatch repair in cancer.
    Baretti M; Le DT
    Pharmacol Ther; 2018 Sep; 189():45-62. PubMed ID: 29669262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mutation characteristics of mismatch and homologous recombination repair genes in gastrointestinal cancer.
    Liu X; Yang H; Wu X; Huang K; Ma P; Jiang P; Zheng W; Tang T; Liu D
    Oncol Lett; 2019 Sep; 18(3):2789-2798. PubMed ID: 31452757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour mismatch repair protein loss is associated with advanced stage in oral cavity squamous cell carcinoma.
    Vasan K; Satgunaseelan L; Anand S; Asher R; Selinger C; Low TH; Palme CE; Clark JR; Gupta R
    Pathology; 2019 Dec; 51(7):688-695. PubMed ID: 31630878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.